KFAR MALAL, Israel, June 13, 2017 /PRNewswire/ --
Medial EarlySign, a developer of machine learning tools
Medial EarlySign develops machine learning-based algorithms to identify individuals at risk of a range of health conditions, including certain cancers, metabolic and other diseases, by analyzing routine EHR data and clinical data such as blood test results. This insight offers healthcare providers the opportunity for earlier intervention and personalized care management plans. The company's first commercialized tool, ColonFlag, has been successfully implemented by integrated delivery networks to identify individuals with an elevated probability for lower GI disorders, enabling organizations to effectively contact, test and treat these patients.
"We believe Gartner's recognition of Medial EarlySign as a Cool AI Healthcare Vendor underscores the value of our predictive technology and its enormous potential to help healthcare providers improve outcomes and meet quality goals by providing the best AI stratification models to leverage their data," said Ori Geva, CEO of Medial EarlySign. "We're honored to be named and look forward to continue developing and implementing our platform across multiple clinical outcomes, to help improve care and reduce healthcare costs."
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Gartner, Cool Vendors in AI for Healthcare, 2017, 15 May 2017.
About Medial EarlySign
Medial EarlySign's advanced algorithm platform accurately detects the likelihood of disease for subpopulations using basic medical information, such as blood test results, and other EMR data. The company's predictive tools provide physicians with actionable insight, while providing insurers with effective models to flag and focus on patients at risk, helping to prioritize resources, save money and improve care. Medial EarlySign's platform addresses numerous potential clinical outcomes, including cancers, diabetes and other life-threatening illnesses. Founded in 2009, the company is headquartered in Kfar Malal, Israel. For more information, please visit http://www.earlysign.com.
Follow Medial EarlySign on LinkedIn: Medial EarlySign and Twitter: @MedialEarlySign
Media Relations Contact: Ellie Hanson Finn Partners +1-929-222-8006 firstname.lastname@example.org
SOURCE Medial EarlySign
Subscribe to our Free Newsletters!
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...
Exotropia or outward eye deviation is a form of squint. Proper evaluation and timely intervention ...
Glaucoma is a group of disorders involving the optic nerve, often associated with a rise in ...View All